Between the continued rise of GLP-1s, the Trump Administration pushing psychedelic medicine closer to a reality, and battles over the 340B drug discount program, pharma companies have had a busy 2026 so far. Looking to the rest of the year, drugmakers will have to focus on issues such as the new Most-Favored-Nation drug pricing policy and a push toward domestic manufacturing. With so much going on in the industry, Healthcare Brew asked pharma leaders to reflect on how they’ve fared so far this year and what their plans are for the rest of 2026.
Read the full article: Pharma Execs Look Back on the First Half of 2026 //
Source: https://www.healthcare-brew.com/stories/pharma-execs-reflect-on-the-first-half-of-2026